Date: June 19, 2025

Written by: Juan Carlos Ocampo-Alvarado

I still remember the one time dengue hit close to home. Not a news report, it was my mom. Vibrant and energetic one day, she was suddenly bedridden, wrestling with a fever so intense, it felt like she was about to break into tiny pieces. Our tools were damp washcloths and prayers. That firsthand glimpse into dengue’s brutal reality solidified something for me: this disease shatters lives and communities. For those of us working on dengue, the journey is about bridging the gap between scientific discovery and societal impact. And nowhere is this more evident than in the contentious world of dengue vaccines.

Developing a dengue vaccine has been one of immunology’s hardest puzzles. Unlike most viral diseases, dengue comes in four distinct serotypes, each capable of causing severe illness. But here’s where things get tricky: while a first dengue infection usually offers solid protection against that specific serotype, it can, counterintuitively, leave you more vulnerable to severe illness if a different serotype strikes later. Scientists call this antibody-dependent enhancement (ADE), and it’s the biological equivalent of a double-edged sword.

Hope meets hesitation (or when the world’s first dengue vaccine ignited controversy)

The arrival of Dengvaxia, the world’s first licensed dengue vaccine, in 2015 was met with excitement. Clinical trials promised a high protective potential against all four serotypes. It felt like a genuine turning point, a victory for global health. The Philippines, a nation long besieged by dengue, became the first country to roll out a mass vaccination program, aiming to protect its children. But the narrative took an unexpected, sobering turn. 

Figure 1: The Dengvaxia vaccine, packaged as powder and solvent for suspension. Its 2015 approval marked a hopeful moment in the fight against dengue. Source: Vol I, McGill Journal of Global Health, September 2020

In late 2017, the vaccine’s manufacturer, Sanofi Pasteur, issued a critical update: Dengvaxia, while effective for those who had previously contracted dengue, posed a risk of increased severe dengue in individuals who had never been infected. This phenomenon (remember ADE?) meant that for a small subset of vaccine recipients, the vaccine could, paradoxically, make a future dengue infection worse.

The aftermath was a whirlwind. The Philippines program was immediately suspended. Public outcry erupted, fuelled by genuine fear, political finger-pointing, and a burgeoning wave of misinformation. The scientific nuance of ADE, a complex immunological concept, was drowned out by sensational headlines and heart-wrenching stories. Trust, once a hard-won bedrock of public health initiatives, crumbled. This wasn’t just a blow to dengue control; it sent ripples of doubt across other vital vaccination programs, a stark reminder of how quickly confidence can erode when communication falters and scientific complexity is lost in translation.

The unfolding Dengvaxia controversy became a textbook example of just how quickly vaccine confidence can unravel. Anti-vaccine groups worldwide seized on the dengue vaccine story as evidence of broader pharmaceutical malfeasance. Social media algorithms amplified sensational headlines while nuanced scientific explanations struggled to gain traction. The narrative, often distorted, was irresistible: a profit-driven company had rushed an unsafe vaccine to market, using children in developing countries as test subjects.

This framing, while emotionally compelling, missed crucial nuances. The Dengvaxia trials were conducted according to international standards, with robust safety monitoring. The enhancement risk, while real, affected a minority of vaccinated children and was only detected through sophisticated post-trial analysis. Regulatory agencies acted swiftly once the issue became clear, updating recommendations and requiring additional studies. Yet these scientific subtleties proved no match for visceral fears and political opportunism.

Why new vaccines still face the human element

From the ashes of the controversy, a new hope emerged: Qdenga. Developed by Takeda, this vaccine, while also a live-attenuated tetravalent vaccine, utilized a different viral backbone. Crucially, its extensive clinical trials were designed with the lessons of Dengvaxia firmly in mind. Data showed consistent efficacy against all four serotypes, and importantly, its safety profile did not demonstrate the same ADE risk in people who had not been infected as with Dengvaxia. This meant no pre-screening for prior infection was required, simplifying its deployment.

Figure 2: A woman receives the Qdenga dengue vaccination in Rio de Janeiro, Brazil, in February, 2024. This ongoing work evaluates the vaccine’s efficacy and safety in real-world settings. Source: Pilar Olivares/Reuters

The World Health Organization’s Strategic Advisory Group of Experts on Immunization has since recommended it for use in high-transmission areas for individuals aged 6-16 years, a testament to its improved safety and efficacy profile. Countries like Brazil, Argentina, and parts of Europe have begun incorporating it into their public health strategies. Yet, even with this progress, uncertainties remain. Ongoing post-market surveillance is crucial to continually monitor its real-world effectiveness and identify any unforeseen long-term effects. Science, after all, is a continuous journey of observation and improvement.

The story of dengue vaccines isn’t just about scientific discovery; it’s about the human element of public health. The Dengvaxia experience amplified an existing global phenomenon: vaccine hesitancy. It’s a hydra-headed beast, fed by a potent mix of legitimate concerns, ingrained distrust, and outright misinformation. 

Imagine Clara, a dedicated community health worker in a small village nestled beside a lush, mosquito-ridden forest. For years, she’s championed childhood immunizations, building trust brick by painstaking brick. Then came the Dengvaxia news, an avalanche of doubt that swept through her community. Parents, once eager, now met her with wary eyes. “Is it truly safe, Clara?” they’d ask, their voices tinged with apprehension. “We heard stories, stories of children falling ill after the shot.” Clara’s struggle highlights the “3 Cs” of vaccine hesitancy:

• Confidence: The erosion of trust in the vaccine itself, the healthcare system, and the authorities promoting it. The Dengvaxia controversy was a seismic event here.
• Complacency: When the perceived risk of the disease is low, people may not see the urgency of vaccination. This is less of an issue with dengue in highly endemic areas, but still a factor.
• Convenience: Practical barriers like accessibility, cost, and scheduling appointments.

Social media, an undeniable force in our interconnected world, acts as both a megaphone and a minefield. While it can disseminate vital public health information, it also allows misinformation to proliferate unchecked, bypassing traditional gatekeepers and reaching vast audiences with alarming speed. Anti-vaccine movements, ever vigilant, deftly exploit genuine concerns and past controversies to sow doubt, often using emotionally charged narratives that resonate far more deeply than dry scientific facts. For young professionals, understanding these dynamics isn’t optional; it’s fundamental to effective intervention.

Diverse, collective action for zero dengue deaths 

So, how do we navigate this nuanced landscape? Here is my take: an unwavering commitment to interdisciplinary collaboration.

Consider the challenge of vaccine deployment. A virologist may understand the intricacies of viral replication, and a public health strategist may devise an ideal rollout plan. But without the insights of a social scientist to understand community beliefs, the expertise of a data scientist to predict localized hesitancy patterns, or the communication skills of an educator to translate complex science into accessible language, even the most perfect vaccine remains an unused tool.

We need epidemiologists to identify high-burden areas and tailor vaccine strategies. We need data scientists to develop predictive models, using climate data, mobility patterns, and even social media sentiment, to anticipate outbreaks and target resources with unprecedented precision. We need engineers to refine mosquito surveillance technologies, providing real-time intelligence for targeted vector control. And perhaps most critically, we need social scientists and community engagement specialists to build genuine relationships, understand local narratives, and co-create solutions with the people most affected. 

This is not a utopian fantasy; it’s the tangible result of diverse minds converging. For the next generation of dengue fighters, the opportunity to bridge these disciplinary divides is immense. We are not confined by past rigidities and siloes. We can champion integrated research that considers both the viral load in a mosquito and the trust levels in a community. We have learnt from past mistakes.

The pursuit of zero dengue deaths demands more than just scientific prowess. It requires a profound understanding of human behaviour, an unwavering commitment to transparent communication, and the courage to build bridges between disciplines. The journey has been marked by both triumphs and losses, but with collective action, rigorous interdisciplinary evidence, and a deep appreciation for the human element, we can move closer to a world free from the shadow of dengue.